Cargando…

Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation

Patients with metabolic syndrome are often prescribed statins to prevent the development of cardiovascular disease. Conversely, data on their effects on non-alcoholic steatohepatitis (NASH) are lacking. We evaluated these effects by feeding APOE*3-Leiden mice a Western-type diet (WTD) with or withou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inia, José A., Stokman, Geurt, Pieterman, Elsbet J., Morrison, Martine C., Menke, Aswin L., Verschuren, Lars, Caspers, Martien P. M., Giera, Martin, Jukema, J. Wouter, van den Hoek, Anita M., Princen, Hans M. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178767/ https://www.ncbi.nlm.nih.gov/pubmed/37175538 http://dx.doi.org/10.3390/ijms24097818

Ejemplares similares

Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
por: Inia, José A., et al.
Publicado: (2023)

Dose Effects of Ammonium Perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP Mice
por: Pouwer, Marianne G, et al.
Publicado: (2019)

The APOE(∗)3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic Atherosclerosis
por: Pouwer, Marianne G., et al.
Publicado: (2019)

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
por: Landlinger, Christine, et al.
Publicado: (2017)

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
por: Pouwer, Marianne G., et al.
Publicado: (2018)

Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol
por: Kühnast, Susan, et al.
Publicado: (2013)

Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice
por: Pouwer, Marianne G., et al.
Publicado: (2020)

Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr‐/‐.Leiden Mice
por: Morrison, Martine C., et al.
Publicado: (2018)

Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men
por: van den Hoek, Anita M., et al.
Publicado: (2021)

Oncostatin M reduces atherosclerosis development in APOE*3Leiden.CETP mice and is associated with increased survival probability in humans
por: van Keulen, Danielle, et al.
Publicado: (2019)

Comment on “Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice” by Rebholz S.L. et al. Toxicol. Rep. 2016 (3) 46–54
por: Princen, Hans M.G., et al.
Publicado: (2016)

Mild Exercise Does Not Prevent Atherosclerosis in APOE*3‐Leiden.CETP Mice or Improve Lipoprotein Profile of Men with Obesity
por: In het Panhuis, Wietse, et al.
Publicado: (2020)

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
por: Kühnast, Susan, et al.
Publicado: (2015)

Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice
por: Schuster, Susanne, et al.
Publicado: (2019)

Heat-Inactivated Akkermansia muciniphila Improves Gut Permeability but Does Not Prevent Development of Non-Alcoholic Steatohepatitis in Diet-Induced Obese Ldlr−/−.Leiden Mice
por: Morrison, Martine C., et al.
Publicado: (2022)

Translational characterization of the temporal dynamics of metabolic dysfunctions in liver, adipose tissue and the gut during diet-induced NASH development in Ldlr−/−.Leiden mice
por: Gart, Eveline, et al.
Publicado: (2023)

Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice
por: van den Hoek, Anita M., et al.
Publicado: (2019)

A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo
por: Suchowerska, Alexandra K., et al.
Publicado: (2022)

Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative
por: Stokman, Geurt, et al.
Publicado: (2020)

Both Transient and Continuous Corticosterone Excess Inhibit Atherosclerotic Plaque Formation in APOE*3-Leiden.CETP Mice
por: Auvinen, Hanna E., et al.
Publicado: (2013)

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
por: Kühnast, Susan, et al.
Publicado: (2014)

Inflammatory cytokine oncostatin M induces endothelial activation in macro- and microvascular endothelial cells and in APOE*3Leiden.CETP mice
por: van Keulen, Danielle, et al.
Publicado: (2018)

Proof-of-concept study for liver-directed miQURE technology in a dyslipidemic mouse model
por: Zancanella, Vanessa, et al.
Publicado: (2023)

Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP mice
por: van Eenige, Robin, et al.
Publicado: (2021)

Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR−/−.Leiden mice
por: Morrison, M C, et al.
Publicado: (2016)

The Human Milk Oligosaccharide 2′-Fucosyllactose Alleviates Liver Steatosis, ER Stress and Insulin Resistance by Reducing Hepatic Diacylglycerols and Improved Gut Permeability in Obese Ldlr-/-.Leiden Mice
por: Gart, Eveline, et al.
Publicado: (2022)

The prebiotic inulin modulates gut microbiota but does not ameliorate atherosclerosis in hypercholesterolemic APOE*3-Leiden.CETP mice
por: Hoving, Lisa R., et al.
Publicado: (2018)

Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice
por: Ying, Zhixiong, et al.
Publicado: (2023)

Plasma and Liver Lipidomics Response to an Intervention of Rimonabant in ApoE*3Leiden.CETP Transgenic Mice
por: Hu, Chunxiu, et al.
Publicado: (2011)

Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice
por: Salic, Kanita, et al.
Publicado: (2019)

P300/CBP Associated Factor (PCAF) Deficiency Enhances Diet-Induced Atherosclerosis in ApoE3(*)Leiden Mice via Systemic Inhibition of Regulatory T Cells
por: de Jong, Alwin, et al.
Publicado: (2021)

The Prebiotic Inulin Aggravates Accelerated Atherosclerosis in Hypercholesterolemic APOE*3-Leiden Mice
por: Hoving, Lisa R., et al.
Publicado: (2018)

A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology
por: van den Hoek, Anita M., et al.
Publicado: (2020)

Cholesterol Accumulation as a Driver of Hepatic Inflammation Under Translational Dietary Conditions Can Be Attenuated by a Multicomponent Medicine
por: Mueller, Andrea M., et al.
Publicado: (2021)

Atherothrombosis model by silencing of protein C in APOE*3-Leiden.CETP transgenic mice
por: Jongejan, Yvonne K., et al.
Publicado: (2021)

Continuous Light Does Not Affect Atherosclerosis in APOE*3-Leiden.CETP Mice
por: Schilperoort, Maaike, et al.
Publicado: (2020)

Therapeutic Intervention with Anti-Complement Component 5 Antibody Does Not Reduce NASH but Does Attenuate Atherosclerosis and MIF Concentrations in Ldlr-/-.Leiden Mice
por: Seidel, Florine, et al.
Publicado: (2022)

Key Inflammatory Processes in Human NASH Are Reflected in Ldlr(−/−).Leiden Mice: A Translational Gene Profiling Study
por: Morrison, Martine C., et al.
Publicado: (2018)

Lipidomics Reveals Multiple Pathway Effects of a Multi-Components Preparation on Lipid Biochemistry in ApoE*3Leiden.CETP Mice
por: Wei, Heng, et al.
Publicado: (2012)

Ldlr-/-.Leiden mice develop neurodegeneration, age-dependent astrogliosis and obesity-induced changes in microglia immunophenotype which are partly reversed by complement component 5 neutralizing antibody
por: Seidel, Florine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9catcgh553h5v1ale14rfcm31v